Can VST Stock Rely on Its Nuclear Assets for Long-Term Stability?
Utilities benefit from operating nuclear power plants by securing stable, low-cost and carbon-free baseload power. These plants run at high capacity factors, generate consistent cash flow and support grid reliability, making them valuable assets in an increasingly decarbonized energy landscape.Dominion Energy D and Constellation Energy CEG have both leveraged their nuclear fleets to strengthen earnings and support clean energy goals. Dominion's North Anna and Surry plants provide steady baseload power, enhancing grid reliability. Constellation Energy, the largest U.S. nuclear operator, generates more than 85% of the output from nuclear, giving it a major cost and emissions advantage in competitive wholesale markets.
Vistra's trailing 12-month return on equity ('ROE') is 87.33%, way ahead of its industry average of 10.41%. ROE, a profitability measure, reflects how effectively a company is utilizing its shareholders' funds in operations to generate income.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Vistra's 2025 and 2026 sales indicates year-over-year increases of 28.91% and 4.53%, respectively.
Image Source: Zacks Investment Research
Shares of Vistra have surged 68.7% in the past three months against the Zacks Utility- Electric Power industry's decline of 0.6%.
Image Source: Zacks Investment Research
Vistra currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Constellation Energy Corporation (CEG) : Free Stock Analysis Report
Dominion Energy Inc. (D) : Free Stock Analysis Report
Vistra Corp. (VST) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
CareBand® Secures New U.S. Patent for Tri-Radio Wearable Architecture Enabling "Everywhere" Low-Power Tracking
CHICAGO, July 22, 2025 /PRNewswire/ -- CareBand, Inc. today announced the award of U.S. Patent 12,298,410, "Wireless Devices, Systems and Methods for Long–Range Radio–Frequency Location Tracking of Objects." The patent protects core logic that lets a single wearable roam automatically among Bluetooth® Low Energy (BLE), nationwide low–power wide–area networks (LPWAN), and direct–to–satellite links, all while using very little battery power. With this latest grant, CareBand's portfolio grows to 16 issued patents that stretch back to 2014. Why this matters now Ubiquitous coverage is finally economical. Global LPWAN revenues are projected to top US $48 billion in 2025 and grow 8–fold by 2030 as logistics, healthcare, and utilities connect mobile assets at scale. (Mordor Intelligence) Space becomes the new cell tower. Multiple mobile operators completed direct–to–orbit voice and data trials over the past year, showing that mass–market devices can now reach satellites when terrestrial service disappears. (The Verge) Bluetooth is breaking its 30–foot leash through mesh. With upgrades like BLE Mesh 1.1, swarms of low–power beacons now knit building– to neighborhood–scale coverage without costly gateways. (Electronic Design) "Back in 2014 we set out to build a discreet wearable for people living with dementia. One that could stay connected to a bedside beacon, then hop to a nationwide low–power network and, if needed, straight to space," said Adam Russek–Sobol, founder and CEO of CareBand. "A decade of R&D later, the market has caught up—and this patent secures the hand–off logic that keeps people and assets visible when legacy tags go dark." What the patent covers Tri–radio decision engine that chooses the cheapest, lowest–energy path, BLE indoors, LPWAN in towns, satellite in the wilderness. Adaptive quality–of–service (QoS) and on–device analytics that prioritise critical health or safety data when bandwidth is scarce. Beacon–defined geofences: caregivers or fleet managers drop beacons to set safe zones, no wiring required. Alert feedback loop: haptic, light, or audible cues on the wearable plus real–time alerts to any web–connected dashboard. Collaboration & LicensingCareBand is actively engaging chipset vendors, device makers, and network operators to license the company's tri–radio IP or co–develop next–generation safety wearables and asset tags. To start a conversation, email sales@ About CareBand develops wearables and software that keep vulnerable people safe and connected. Built on a decade of R&D, CareBand's platform delivers real-time location, fall detection, and behavioral insights over the world's lowest-power networks. Media Contact:media@ View original content: SOURCE CareBand, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 minutes ago
- Yahoo
GM stock buckles under multiple headwinds and risky bets on EVs
General Motors (GM) is navigating a rocky road as Trump tariffs hit its profits while its EV efforts face an uncertain future. The storied automaker reported that net income dropped 35% year over year, as tariffs hit its profit by $1.1 billion during the quarter. GM warned the toll could grow in the second half of the year, reiterating its previous estimate of a $4 billion to $5 billion hit for the year. Shares dropped 7% during the day, even as the company's adjusted earnings per share of $2.53 and revenue of $47.1 billion beat Bloomberg consensus estimates of $2.33 and $46.27 billion, respectively. Its stock is down 4% year to date. GM said it's 'making solid progress' in mitigating at least 30% of the expected tariff burden through manufacturing and supply chain shifts. Those include a $4 billion investment in US-based assembly plants, which will add 300,000 units of production capacity for light-duty pickups, full-size SUVs, and crossovers. CEO Mary Barra said on its earnings call that "GM expects to build over 2 million US vehicles annually within 18 months." Citi analyst Michael Ward noted it appears GM is "prepared for the worst case scenario, so there's potential for some upside the way we look at it." GM's underlying results showed some resilience. During Q2, it sold 974,000 vehicles, a 7.3% increase year-over-year. It sold 46,300 electric vehicles, up from 31,900 last quarter. RBC Capital's Tom Narayan said in a research note there's a broader market trend where companies report earnings "beats and/or raises are still seeing stock sell-offs." He said it reflects investor concerns about tariffs, rising costs, and a challenging macroeconomic environment. For GM, its EV division's profitability also remains uncertain, as competition heightens and consumer demand slows. The $7,500 federal EV tax credit, key to EV's affordability, expires in September. Barclays analysts Dan Levy said "these changes indicate profitability is probably gonna get a little trickier." GM was supposed to use scale to drive profit for EVs, which is harder to do when sales are slowing, Levy added. Barra, however, reaffirmed the company's commitment to profitability on every EV model. She did not provide a hard timeline, but said "I'm very bullish on where we're gonna be on EVs as we continue to move forward in the next couple of years." Meanwhile, GM is regaining ground in China, with profitable joint ventures, new hybrid models, and tighter inventory control. The company posted year-over-year sales growth in the region for the second consecutive quarter, and returned to profitability this quarter.
Yahoo
14 minutes ago
- Yahoo
Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline
Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the consensus of $5.84 billion. The life science giant reported adjusted earnings of $1.80 per share, beating the consensus of $1.64. Non-GAAP core revenue increased 1.5% year over year, compared to the expectations of a growth in low single digits year over year. Operating cash flow was $1.3 billion, and non-GAAP free cash flow was $1.1 billion. Danaher's second-quarter adjusted operating profit margin of 27.3% exceeded expectations of around 25.5%.Biotechnology sales increased to $1.85 billion compared to $1.71 billion a year ago, with core growth of 6%. Sales in the Life Sciences segment remained flat at $1.78 billion, and diagnostic sales increased from $2.26 billion to $2.31 billion. The company said, "DBS-driven execution, paired with another quarter of +HSD growth in Bioprocessing and disciplined cost management, enabled us to exceed our Q2 adjusted EPS and cash flow expectations." Guidance Danaher raised fiscal 2025 adjusted earnings guidance from $7.60-$7.75 per share to $7.70-$7.80, compared to the consensus of $7.70. The company cites good traction on cost initiatives. View more earnings on DHR Danaher reaffirms that in fiscal year 2025, non-GAAP core revenue will grow by approximately 3% year over year. Cepheid 2025 respiratory revenues will be around $1.7 billion. The company expects an adjusted operating profit margin of around 25.5%. Biotechnology core revenue growth is expected to be approximately 6% for the third quarter of 2025 and around 7% for the fiscal year 2025. Life sciences core revenue will remain flat for the third quarter and fiscal year 2025. Diagnostics sales are expected to increase in the low single digits in the third quarter and flat to low single digits in fiscal year 2025. Management update Danaher announced Matthew Gugino, currently group CFO of Life Sciences Innovations Group and VP of Financial Planning & Analysis, will succeed Matthew McGrew as Danaher's CFO, effective February 28, 2026. Analyst Opinion William Blair writes that the macro backdrop for life science tools and bioprocessing companies was anything but sanguine in the second quarter, with escalating concerns surrounding the funding environment, tariffs, MFN, and whether these uncertainties resulted in a slowdown in the overall demand environment." Danaher's results suggest that was not the case, at least in the second quarter, particularly within bioprocessing. Analyst Matt Larew maintains the Outperform rating. Price Action: DHR stock is trading 0.68% higher at $189.34 at the last check on Tuesday. Read Next:Photo via Shutterstock Latest Ratings for DHR Date Firm Action From To Jan 2022 Wells Fargo Maintains Overweight Jan 2022 Barclays Maintains Overweight Jan 2022 Bernstein Initiates Coverage On Outperform View More Analyst Ratings for DHR View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? DANAHER (DHR): Free Stock Analysis Report This article Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
